Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the company to lose more than 40% of their value in pre-market trading. The news is ...
If you purchase an independently reviewed product or service through a link on our website, Rolling Stone may receive an affiliate commission. Whether you’re looking for a night or two off negronis, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback